Dr. Richard G. Moore
Claim this profileUniversity of Rochester
Area of expertise
Endometrial Adenocarcinoma
Richard G. Moore has run 6 trials for Endometrial Adenocarcinoma. Some of their research focus areas include:
Uterine Cancer
Richard G. Moore has run 5 trials for Uterine Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Rochester
Highland Hospital
Clinical Trials Richard G. Moore is currently running
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting
2 awards
Phase 3
CA 125 Blood Test
for Early Detection of Ovarian Cancer
The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are substances in the blood that may be related to ovarian cancer.
Recruiting
1 award
N/A
7 criteria
More about Richard G. Moore
Clinical Trial Related
3 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Richard G. Moore has experience with
- Carboplatin
- External Beam Radiation Therapy
- Pembrolizumab
- Cisplatin
- Laboratory Biomarker Analysis
- Paclitaxel
Breakdown of trials Richard G. Moore has run
Endometrial Adenocarcinoma
Uterine Cancer
Carcinosarcoma
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard G. Moore specialize in?
Richard G. Moore focuses on Endometrial Adenocarcinoma and Uterine Cancer. In particular, much of their work with Endometrial Adenocarcinoma has involved Stage IV patients, or patients who are Stage I.
Is Richard G. Moore currently recruiting for clinical trials?
Yes, Richard G. Moore is currently recruiting for 4 clinical trials in Rochester New York. If you're interested in participating, you should apply.
Are there any treatments that Richard G. Moore has studied deeply?
Yes, Richard G. Moore has studied treatments such as Carboplatin, External Beam Radiation Therapy, Pembrolizumab.
What is the best way to schedule an appointment with Richard G. Moore?
Apply for one of the trials that Richard G. Moore is conducting.
What is the office address of Richard G. Moore?
The office of Richard G. Moore is located at: University of Rochester, Rochester, New York 14642 United States. This is the address for their practice at the University of Rochester.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.